About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
ADCs & Targeted Therapies for Advanced TNBC: Can Sacituzumab Govitecan Improve PFS? Should We Use Tala vs. Chemo for BRCA1/2 Patients? Is Olaparib Mono a New SoC?
By
3rd Annual Atlanta Precision Oncology Symposium
FEATURING
Jennifer Litton
By
3rd Annual Atlanta Precision Oncology Symposium
FEATURING
Jennifer Litton
90 views
February 12, 2021
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
London Breast Meeting
London Breast Meeting 2024
Wed, Sep 4, 2024
12:35
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…
Feat.
S. Tolaney,
H. Rugo
14:16
Dana-Farber Cancer Institute
Year in Review: Breast Cancer
Feat.
P. Tarantino
17:20
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…
Feat.
P. Tarantino
04:28
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …
Feat.
S. Tolaney
49:07
SABCS 2022 Conference Coverage
SABCS 2022 Expert Panel Discussion: Practice-Changing Updates
Feat.
J. O'Shaughnessy,
S. Tolaney,
S. Hurvitz,
H. Rugo
07:50
Oncology Data Advisor
ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…
Feat.
K. Kalinsky
22:34
Dana-Farber Cancer Institute
What's New in Breast Cancer?
Feat.
S. Tolaney
17:35
Insights from 2023 SABCS
SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…
Feat.
P. Tarantino
30:46
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"
Feat.
S. Tolaney,
H. Rugo
24:36
ESMO 2022 Conference Coverage
ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates
Feat.
H. Rugo,
J. O'Shaughnessy
24:10
Keck School of Medicine of USC
CDK4/6 Inhibitors in Breast Cancer: 2024 Update
Feat.
R. O'Regan
21:37
Dana-Farber Cancer Institute
Standard Treatments for HR+/HER2- mBC in 2023
Feat.
S. Sammons
27:01
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024
CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC
Feat.
S. Sammons
29:40
Insights from 2023 SABCS
Year in Review: Metastatic Breast Cancer
Feat.
M. Mac Gregor
12:21
Insights from 2023 SABCS
SABCS 2023 Insights: "How to Treat TNBC"
Feat.
P. Sharma
03:24
ecancer
SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…
Feat.
V. Kaklamani
02:35
Integrity Continuing Education
SABCS 2023 Summary: "monarchE & NATALEE Trials - Adjuvant T…
Feat.
A. Bardia
20:42
Total Health
2022 Updates in TNBC
Feat.
I. Schlam
13:23
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…
Feat.
S. Hurvitz
20:16
University of Colorado Cancer Center
Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…
Feat.
V. Borges
